MLTX
MoonLake Immunotherapeutics
There isn't enough reported data to score MLTX yet.
MLTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MLTX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MLTX PE Valuation
MLTX has no meaningful PE right now: it lost money over the past year.
MLTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect MLTX's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
MLTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -$0.36 |
| Q2 2026 | -$3.85 | -$1.07 |
| Q1 2026 | -$3.88 | -$1.58 |
| Q4 2025 | -$3.53 | -$1.64 |
| Q3 2025 | -$3.32 | -$2.06 |
| Q2 2025 | -$2.78 | -$1.90 |
| Q1 2025 | -$2.30 | -$1.58 |
| Q4 2024 | -$1.89 | -$1.16 |
MLTX lost $3.68 per share over the past year, a bigger loss than the year before.
MLTX Quarterly Revenue
MLTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$63.4M | -$18.9M |
| Q2 2026 | -$55.6M | -$1M |
| Q1 2026 | -$66.3M | -$28.1M |
| Q4 2025 | -$58.8M | -$10.1M |
| Q3 2025 | -$44.5M | -$19.1M |
| Q2 2025 | -$54.5M | -$26.6M |
| Q1 2025 | -$38.2M | -$23M |
| Q4 2024 | -$48.6M | -$36M |
MLTX has burned cash in almost every quarter: −$244M over the past year, against −$186M the year before.
MLTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +11.5M shares |
| 1 year | +35% | +22M shares |
| 3 years | +95% | +41.7M shares |
MLTX has 85M diluted shares, up 35% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $50.00 |
| Q1 2021 | — |
| Q4 2020 | — |
MLTX Net Leverage
MLTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MLTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 28.5 | Neutral |
MLTX's weekly RSI is 42 (neutral) and its Stochastic is 29 (neutral).
MLTX PE vs Healthcare Sector
MLTX has no meaningful PE right now: it lost money over the past year.
MLTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 12% above |
| 20 week MA | $14.7 | 12% below |
| 50 week MA | $16.0 | 20% below |
| 100 week MA | $28.0 | 54% below |
| 200 week MA | $35.9 | 64% below |
MLTX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 64% below its 200-week average.
MLTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.6 | $11.0 | +4.4% |
| 2021 | $11.0 | $9.89 | -10% |
| 2022 | $9.89 | $10.0 | +1.1% |
| 2023 | $10.0 | $60.4 | +504% |
| 2024 | $60.4 | $55.4 | -8.3% |
| 2025 | $55.4 | $13.8 | -75% |
| 2026 YTD | $13.8 | $12.9 | -6.9% |
MLTX's yearly returns have swung widely, from +504% in 2023 to −75% in 2025. It's down 6.9% so far in 2026.